A Randomised Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir (TPV) Plus 100 mg or 200 mg Ritonavir (RTV) p.o. BID in Comparison to 400 mg Lopinavir (LPV) Plus 100 mg RTV p.o. BID in Combination With Standard Background Regimen in ARV Therapy naïve Patients.

NCT00144105 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

562

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: TPV500mg/RTV200mgBID
DRUG: TPV500mg/RTV100mgBID
DRUG: LPV400mg/RTV100mgBID

Sponsor

Boehringer Ingelheim